News | November 10, 2025
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Relmada expects to initiate its Phase 3 program in the first half of 2026
The said inspection concluded with Zero Form 483 observation
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Subscribe To Our Newsletter & Stay Updated
